Anika Therapeutics CEO exercises 12,840 RSUs
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Anika Therapeutics, Inc. President and CEO Stephen D. Griffin reported the vesting of 12,840 restricted stock units on June 3, 2026, which converted into 12,840 shares of common stock at no cash cost as the second of three equal annual installments from a 38,520-RSU grant awarded on June 3, 2024.
To satisfy tax withholding obligations on this vesting, the issuer retained 3,769 shares at $14.41 per share. After these transactions, Griffin directly holds 45,973 shares of Anika common stock, including 739 shares acquired on May 14, 2026 under the company’s Employee Stock Purchase Plan.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 12,840 | $0.00 | $0.00 |
| Exercise | Common Stock | 12,840 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 3,769 | $14.41 | $54K |
Footnotes (4)
- F1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.
- F2. Includes 739 shares acquired on May 14, 2026 under the Anika Therapeutics, Inc. Employee Stock Purchase Plan.
- F3. Reflects an aggregate of 3,769 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on June 3, 2026.
- F4. On June 3, 2024, the Reporting Person was granted 38,520 RSUs vesting in three equal annual installments beginning on June 3, 2025. This transaction reflects the second vesting installment of such RSU award.
Key Figures
Key Terms
Restricted Stock Unit financial
tax withholding obligations financial
Employee Stock Purchase Plan financial
derivative security financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What RSU transaction did Anika Therapeutics (ANIK) CEO Stephen D. Griffin report?
What RSU grant schedule led to the June 3, 2026 vesting for ANIK’s CEO?
Were the ANIK CEO’s June 3, 2026 transactions open-market purchases or sales?
AI-generated analysis. How Rhea-AI works. Not financial advice.